These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17684975)

  • 21. Autologous anticancer antigen preparation for specific immunotherapy in advanced renal cell carcinoma.
    Kurth KH; Marquet R; Zwartendijk J; Warnaar SO
    Eur Urol; 1987; 13(1-2):103-9. PubMed ID: 3582439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The immunotherapy of advanced renal cell carcinoma].
    Bergmann L; Weidmann E; Mitrou PS
    Dtsch Med Wochenschr; 1991 Mar; 116(10):384-90. PubMed ID: 1705879
    [No Abstract]   [Full Text] [Related]  

  • 23. Prognostic factors of immunotherapy in metastatic renal cell carcinoma.
    Padrik P
    Med Oncol; 2003; 20(4):325-34. PubMed ID: 14716028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kidney cancer: Combining targeted and immunotherapy.
    Thoma C
    Nat Rev Urol; 2018 May; 15(5):263. PubMed ID: 29620060
    [No Abstract]   [Full Text] [Related]  

  • 26. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
    Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J
    Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5T4 as a target for immunotherapy in renal cell carcinoma.
    Elkord E; Shablak A; Stern PL; Hawkins RE
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1705-9. PubMed ID: 19954280
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunotherapy for renal cell cancer.
    Bower M; Roylance R; Waxman J
    QJM; 1998 Sep; 91(9):597-602. PubMed ID: 10024913
    [No Abstract]   [Full Text] [Related]  

  • 29. Renal cell carcinoma and interleukin-2: what are the endpoints?
    Figlin RA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S68-9. PubMed ID: 9457397
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunotherapy of metastatic renal cell cancer.
    Goey SH; Verweij J; Stoter G
    Ann Oncol; 1996 Nov; 7(9):887-900. PubMed ID: 9006738
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunotherapy for metastatic renal cell carcinoma.
    McDermott DF; Rini BI
    BJU Int; 2007 May; 99(5 Pt B):1282-8. PubMed ID: 17441925
    [No Abstract]   [Full Text] [Related]  

  • 32. [Basic and clinical analysis of immune cell therapy against advanced renal cell carcinoma].
    Eto M; Naito S
    Fukuoka Igaku Zasshi; 2007 Oct; 98(10):357-63. PubMed ID: 18046988
    [No Abstract]   [Full Text] [Related]  

  • 33. Editorial: current strategies in advanced renal cell carcinoma.
    Haddad AQ; Margulis V; Schmidinger M
    Curr Opin Urol; 2015 Sep; 25(5):357. PubMed ID: 26222928
    [No Abstract]   [Full Text] [Related]  

  • 34. Prognostic factors and molecular markers for renal cell carcinoma.
    Bui MH; Zisman A; Pantuck AJ; Han KR; Wieder J; Belldegrun AS
    Expert Rev Anticancer Ther; 2001 Dec; 1(4):565-75. PubMed ID: 12113089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
    Belldegrun A; Shvarts O; Figlin RA
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination immunotherapy in renal cell carcinoma.
    Drake CG
    Clin Adv Hematol Oncol; 2016 Feb; 14(2):99-100. PubMed ID: 27057808
    [No Abstract]   [Full Text] [Related]  

  • 37. The emergence of modern cancer immunotherapy.
    Rosenberg SA
    Ann Surg Oncol; 2005 May; 12(5):344-6. PubMed ID: 15843873
    [No Abstract]   [Full Text] [Related]  

  • 38. Re: ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting.
    Rassweiler J
    Eur Urol; 2012 Jan; 61(1):219-20. PubMed ID: 22122872
    [No Abstract]   [Full Text] [Related]  

  • 39. No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?
    Kwak C; Park YH; Jeong CW; Lee SE; Ku JH
    Urol Oncol; 2007; 25(4):310-6. PubMed ID: 17628297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
    De Lichtenberg TH; Hermann GG; Rørth M; Højer Larsen MJ; Mansourvar Z; Holm ML; Scheike T
    Scand J Urol; 2014 Aug; 48(4):379-86. PubMed ID: 24521185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.